Skip to main content
RXST logo

RxSight, Inc. (RXST) Stock: Price, Forecast & Analyst Target

RxSight, Inc. (RXST) — MoonshotScore 20/100 (Weak band), calculated Nov 18, 2026. Price $4.61 (-7.98%), as of the Nov 19, 2026 trading session; market cap $193M.

Educational signal · not a buy or sell recommendation · How to read this

$4.61 −$0.40 (-7.98%) Market Cap $193M

RxSight, Inc. · RXST · NASDAQ

RxSight, Inc. is a medical technology company specializing in light adjustable intraocular lenses (LALs) for cataract surgery. Their RxSight system allows doctors to customize and enhance patients' vision after cataract surgery using a light delivery device.

Price as of Nov 19, 2026

Key Statistics

20 of 100

MoonshotScore v2 · RxSight (RXST)

Weak
Business Quality Average (46)
Financial Safety Strained (34)
Valuation Fair (77)
Growth Durability Flat (48)
Momentum Slipping (39)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

A strained balance sheet, though quality and growth are only middling. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Average; Financial Safety: Strained; Valuation: Fair; Growth Durability: Flat; Momentum: Slipping.

  • quarterly revenue $25M (Q3 FY2026, quarter ended Sep 30, 2026)
  • EPS beat 5 of the last 8 reports
  • Altman Z -0.79 · Piotroski F 2

Holding back: balance-sheet strain

Helping: an attractive price

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for RXST (57 recorded, newest six shown)
RecordedScoreBand
24Weak
20Weak
20Weak
20Weak
20Weak
20Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$4.61
Change on the day-7.98%
52-week range$4.11 – $13.22
Market capitalisation$193M—
Shares traded on the day798.4K

Price & events

Other perspectives

Council score for RxSight (RXST): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Neutral
Financial Safety Weak
Valuation Moderate
Growth Durability Neutral
Momentum Weak

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Neutral read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Sep 21, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Negative
Debt/Equity Strong
ROE Negative
Gross Margin Strong

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is RxSight (RXST), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. RxSight, Inc. (RXST) is listed on NASDAQ. It employs 461 people and is led by Aziz Mottiwala. In Q3 FY2026 it reported revenue of $25M and net income of -$16M. The market values it at $193M.

2 · Latest results

What do the latest results show for RxSight (RXST)?

Short answer · as of

The most recent reported quarter, Q3 FY2026, carried revenue of $25M. Against analyst estimates the company has EPS beat 5 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2026$25M-$16M-$0.39 (diluted)
Q2 FY2026$34M-$12M-$0.29 (diluted)
Q1 FY2026$31M-$16M-$0.38 (diluted)
Q4 FY2025$33M-$9M-$0.22 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for RxSight (RXST)?

Short answer · as of

The MoonshotScore pillars rate an attractive price as strengths. What is holding it back is balance-sheet strain. The distress and quality screens read Altman Z -0.79 · Piotroski F 2. Trailing ratios: ROE -20.1% · ROA -15.7% · current ratio 4.20 · earnings yield -24.0% · free-cash-flow yield 8.4%.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of -0.79 sits in the distress zone (elevated bankruptcy risk).
  • Negative return on equity (-20.1%) — the business is not currently generating profit on shareholder capital.
  • Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
4 · What to check next?

What should you watch next at RxSight (RXST)?

Short answer · as of

Current published price targets run low $5.50 · high $7.00 · consensus $6.06 · median $5.88 against a quoted price of $4.61 (as of Nov 19, 2026).

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.
  • No insider Form 4 transaction falls inside the window this page reads.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does RxSight compare with its peers?

Short answer

RxSight's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Tactile Systems Technology, Inc. (TCMD) Same industry, near in market value$26.42 Nov 18, 2026$592M90 5-pillar Nov 18, 2026
Viemed Healthcare, Inc. (VMD) Same industry, near in market value$8.61 Nov 19, 2026$326M88 5-pillar Nov 18, 2026
Electromed, Inc. (ELMD) Same industry, near in market value$23.40 Nov 18, 2026$191M87 5-pillar Nov 18, 2026
BrainsWay Ltd. (BWAY) Same industry, near in market value$8.98 Nov 18, 2026$361M87 5-pillar Nov 18, 2026
Johnson & Johnson (JNJ) Named competitor$272.70 Nov 18, 2026$656B83 5-pillar Nov 18, 2026
Alcon Inc. (ALC) Named competitor$74.52 Nov 19, 2026$35.8B80 5-pillar Nov 18, 2026
Anika Therapeutics, Inc. (ANIK) Same industry, near in market value$13.28 Nov 19, 2026$178M71 5-pillar Nov 18, 2026
Solana Company (HSDT) Same industry, near in market value$1.66 Nov 19, 2026$104M43 5-pillar Nov 18, 2026
Owlet, Inc. (OWLT) Same industry, near in market value$3.67 Nov 18, 2026$110M41 5-pillar Nov 18, 2026
Inogen, Inc. (INGN) Same industry, near in market value$5.42 Nov 19, 2026$141M37 5-pillar Nov 18, 2026
Orthofix Medical Inc. (OFIX) Same industry, near in market value$6.34 Nov 19, 2026$258M36 5-pillar Nov 18, 2026
908 Devices Inc. (MASS) Same industry, near in market value$9.52 Nov 18, 2026$396M35 5-pillar Nov 18, 2026
RxSight (RXST) — this page$4.61$193M20

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$5.50 – $7.00
Consensus target
$6.06
Median target
$5.88

Consensus record · Captured .

Measured against a quoted price of $4.61 (as of Nov 19, 2026).

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held RXST in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported RXST in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

RxSight Stock: Key Questions Answered

These answers are editorial: 1 of these 9 answers is drawn from the RXST research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for RXST?

RXST carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. RxSight, Inc. is a medical technology company specializing in light adjustable intraocular lenses (LALs) for cataract surgery.

Is RXST a good stock to buy?

Stock Expert AI does not rate RXST buy, sell or hold. RxSight, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the RXST stock price today?

The last price recorded for RxSight, Inc. (RXST), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the RXST price target?

The analyst consensus price target for RxSight, Inc. (RXST), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What revenue streams does RxSight, Inc. have in healthcare?

RxSight, Inc.'s primary revenue streams are derived from the sale of its Light Adjustable Lenses (LALs) and Light Delivery Devices (LDDs).

What are the key factors to evaluate for RXST?

RxSight, Inc. (RXST) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. RxSight's RxSight system includes the Light Delivery Device (LDD), an office-based treatment that customizes the LAL. Not financial advice.

How frequently does RXST data refresh on this page?

RXST's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven RXST's recent stock price performance?

RxSight, Inc. (RXST) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative Light Adjustable Lens (LAL) technology. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider RXST overvalued or undervalued right now?

RxSight, Inc. (RXST) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 19 figures on this page — 11 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.